Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Recurium IP Holdings
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Recurium IP Holdings develops, patents, and licenses novel therapeutics mainly for oncology, spanning modalities such as antibody-drug conjugates targeting ROR1, PROTACs for Wee1 kinase, and estrogen receptor modulators; the company's programs are mostly preclinical/patent-stage, aimed at enabling other firms’ pipeline and partnering for clinical development.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Antibody-drug conjugateProteolysis-targeting chimera therapySmall moleculePeptides
- Industry
- Biotech
02
Partnerships
Zentalis Pharmaceuticals (IP licensing relationship)Kalyra Pharmaceuticals (historical licensing/asset transfer)
Beyond the preview
Go deeper on Recurium IP Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recurium IP Holdings.